Eisai and Biogen launch Alzheimer's drug Leqembi in China

(Reuters) - Eisai and Biogen have launched their Alzheimer's treatment Leqembi in China, the third country after the United States and Japan, the companies said on Friday.

Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease.

The drug will first be launched in the private market at 2,508 yuan ($345.04) for a 200 mg vial, the companies said in a statement.

Eisai has also collaborated with a major Chinese medical insurance firm to plan partial coverage of the drug cost, the companies said without naming the insurer.

China approved the treatment in January after a standard approval from the U.S. Food and Drug Administration last July.

More convenient Alzheimer's blood tests expected to be ready by 2025 could help Eisai reach a bigger share of China's estimated 17 million people with early-stage disease, a company spokesperson had told Reuters after approval in China.

($1 = 7.2688 Chinese yuan)

(Reporting by Surbhi Misra in Bengaluru; Editing by Subhranshu Sahu)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Medicare Advantage premiums expected to drop more than 16% in 2027, CMS projects
• Exclusive-Tiger Global, Dragoneer in talks to invest in Kalshi's new $1 billion fundraise, sources say 
• OpenAI takes on Meta with always-on Dots agent in enterprise AI push